Literature DB >> 29544969

Cutibacterium (Formerly Propionibacterium) avidum: A Rare but Avid Agent of Prosthetic Hip Infection.

Valérie A Zeller1, Valérie-Anne Letembet1, Vanina A Meyssonnier1, Beate Heym2, Jean-Marc Ziza1, Simon D Marmor3.   

Abstract

BACKGROUND: Cutibacterium spp. (formerly Propionibacterium) are slow-growing cutaneous anaerobic commensals, rarely reported in prosthetic joint infections (PJIs). We describe epidemiological, clinical, biological, and radiological characteristics of 15 Cutibacterium avidum PJIs, their treatments, and outcomes.
METHODS: This study is an observational, monocenter study (January 2004 to April 2017), with comparison of C avidum vs Cutibacterium acnes (n = 40) PJI characteristics.
RESULTS: Among 1179 PJIs treated during the study period, 15 (1%) PJIs were due to C avidum (14 classified as late chronic and 1 as early postoperative). They involved only obese patients with hip arthroplasties (median age 65 years, body mass index 35 kg/m2). Twelve patients' PJIs developed after primary hip arthroplasty. Thirteen patients' last clean operation had used an anterior approach. Fourteen preoperative joint aspirate cultures yielded C avidum. The 14 chronic PJIs were treated with 1-stage exchange arthroplasty, the acute case with excision synovectomy. Antibiotic therapy was administered for 12 [6-13] weeks, intravenously for 4 [2-6] weeks. The most used first-line agents were intravenous clindamycin (n = 8) or cefazolin (n = 6). After median follow-up of 27 [3-136] months, 1 relapse occurred. Compared to C acnes PJI patients, those with C avidum PJIs were significantly younger, had higher body mass indices, had only hip involvement, and had more frequent anterior surgical approach. C acnes PJIs were more frequent after revision arthroplasty.
CONCLUSION: C avidum is a rare PJI agent occurring in a particular subpopulation. Joint aspiration is the key diagnostic tool. Our results suggest that PJI risk factors include obesity, primary hip arthroplasty, and anterior surgical approach. Efforts to prevent these infections in high-risk patients should be developed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutibacterium (Propionibacterium) avidum; anterior approach; obesity; one stage exchange arthroplasty; primary hip arthroplasty; prosthetic hip infection

Mesh:

Substances:

Year:  2018        PMID: 29544969     DOI: 10.1016/j.arth.2018.02.008

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

Review 1.  Clinical and Biological Features of Cutibacterium (Formerly Propionibacterium) avidum, an Underrecognized Microorganism.

Authors:  Stéphane Corvec
Journal:  Clin Microbiol Rev       Date:  2018-05-30       Impact factor: 26.132

Review 2.  Antibiotic Therapy for Prosthetic Joint Infections: An Overview.

Authors:  Benjamin Le Vavasseur; Valérie Zeller
Journal:  Antibiotics (Basel)       Date:  2022-04-05

3.  Simultaneous Propionibacterium avidum and Propionibacterium acnes Chronic Periprosthetic Hip Joint Infection: A Case Report.

Authors:  Stefano Gussago; Luigia Elzi; Michele Arigoni; Cristiana Poroli Bastone; Mauro N Molina
Journal:  Cureus       Date:  2021-12-28

4.  Orthopedic implant-associated infections caused by Cutibacterium spp. - A remaining diagnostic challenge.

Authors:  Nora Renz; Stasa Mudrovcic; Carsten Perka; Andrej Trampuz
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

5.  Surgical outcomes of infectious spondylitis after vertebroplasty, and comparisons between pyogenic and tuberculosis.

Authors:  Jen-Chung Liao; Po-Liang Lai; Lih-Hui Chen; Chi-Chien Niu
Journal:  BMC Infect Dis       Date:  2018-11-12       Impact factor: 3.090

6.  Cutibacterium avidum resists surgical skin antisepsis in the groin-a potential risk factor for periprosthetic joint infection: a quality control study.

Authors:  Steven M Maurer; Laura Kursawe; Stefan Rahm; Julia Prinz; Annelies S Zinkernagel; Annette Moter; Stefan P Kuster; Reinhard Zbinden; Patrick O Zingg; Yvonne Achermann
Journal:  Antimicrob Resist Infect Control       Date:  2021-02-01       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.